STA
ZYNE

Summit Trail Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Summit Trail Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25
Closed – – 1788
2017
Q4 		$0 Buy
+25
New +$287 ﹤0.01% 2119

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's ZYNE Position: Q1 2018 in Review

Summit Trail Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2018, closing a stake of 25 shares.

Summit Trail Advisors first reported a position in ZYNE in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2018.

  • Summit Trail Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 25 Zynerba Pharmaceuticals, Inc shares in Q1 2018.
  • Summit Trail Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Zynerba Pharmaceuticals, Inc position peaked at $0 in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.